Retatrutide vs 5-Amino-1MQ
Compare the research profiles of Retatrutide and 5-Amino-1MQ. Read the individual guides for evidence and limitations.
How to interpret this comparison
This page summarizes database profiles and has not yet received a study-by-study editorial review. These compounds are filed under different research categories, so a direct treatment comparison may not answer a meaningful clinical question. Use the linked guides and primary sources to evaluate a specific claim.
How to read peptide studiesRetatrutide
Retatrutide (LY3437943)
weight-loss
Phase 3 Clinical Trials
clinical-trials
5-Amino-1MQ
5-Amino-1-Methylquinolinium
metabolic
Preclinical
not-approved
Detailed Comparison
| Aspect | Retatrutide | 5-Amino-1MQ |
|---|---|---|
| Overview | A triple hormone receptor agonist (GLP-1/GIP/Glucagon) in clinical trials by Eli Lilly. Shows remarkable weight loss results up to 29% body weight. Often misleadingly called "GLP-3" on gray market.... | A small molecule peptide gaining traction for targeting visceral fat and activating NAD+ levels to boost metabolic rate. Works by inhibiting NNMT enzyme.... |
| Research topics (not established benefits) |
|
|
| Side Effects |
|
|
| Mechanism | Activates three receptors simultaneously: GLP-1, GIP, and glucagon. The glucagon component may provide additional metabolic benefits and fat burning.... | Inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that when overexpressed leads to fat accumulation. Blocking NNMT increases NAD+ levels and... |
Frequently Asked Questions
Does a comparison establish which treatment is better?
Only appropriately designed evidence for the same clinical question can support that conclusion. Database categories and mechanisms alone cannot rank treatments.
Does this page establish that these compounds can be combined?
No. This page does not assess interactions or the benefit and safety of combined use. Individual studies cannot establish the effects of a combination.